Cystic Fibrosis (CF)

Also known as: Cystic Fibrosis / Mucoviscidosis / Fibrosis, Cystic / CF / Cystic fibrosis NOS

DrugDrug NameDrug Description
DB00003Dornase alfaDornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.
DB01050IbuprofenIbuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
DB08820IvacaftorIvacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF) in patients aged 2 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes [A20298, A20299]. As a result, CF patients produce a thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition [A20302]. Use of Ivacaftor has been shown to both improve CF symptoms and modulate underlying disease pathology. This is achieved by potentiating the channel opening probability (or gating) of CFTR protein in patients with impaired gating mechanisms. This is in contrast to [DB09280], another CF medication, that functions by preventing misfolding of the CFTR protein and thereby results in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with ivacaftor results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms [FDA Label]. This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi (lumacaftor/ivacaftor) [A20343]. A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes [A20301]. Ivacaftor as monotherapy has failed to show a benefit for patients with delta-F508 mutations, most likely due to insufficient amount of protein available at the cell membrane for interaction and potentiation by the drug[A20305]. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered [A17564]. Ivacaftor is indicated for the management of CF in patients with this second type of mutation, as it binds to and potentiates the channel opening ability of CFTR proteins on the cell membrane [A17564]. Although ivacaftor has not shown any significant improvements in patients with the delta-F508 mutation, it has shown significant improvements (>10% increase in FEV1 from baseline) in lung function for the following mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [FDA Label]. This list was expanded by the FDA in May 2017 from 10 to 33 to accomodate more rare mutations [L768]. When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation (see above list of susceptible mutations). When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms [A20297]. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012 and by Health Canada on November 26, 2012.
DB09280LumacaftorLumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes [A20298, A20299]. As a result, CF patients produce a thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition [A20302]. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms [FDA Label]. This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi [A20343]. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5% [A20343, L936]. A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes [A20301]. When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport [A18395]. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered [A17564]. Treatment of patients with G551D and other rarer missense mutations is usually managed with [DB08820] (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and [DB08820] (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals.
DrugDrug NameTargetType
DB00003Dornase alfaDNAtarget
DB01050IbuprofenProstaglandin G/H synthase 1target
DB01050IbuprofenProstaglandin G/H synthase 2target
DB01050IbuprofenCytochrome P450 2C9enzyme
DB01050IbuprofenSerum albumincarrier
DB01050IbuprofenMultidrug resistance-associated protein 4transporter
DB01050IbuprofenMultidrug resistance-associated protein 1transporter
DB01050IbuprofenSolute carrier organic anion transporter family member 1A2transporter
DB01050IbuprofenSolute carrier family 22 member 6transporter
DB01050IbuprofenSolute carrier family 22 member 8transporter
DB01050IbuprofenSolute carrier family 22 member 11transporter
DB01050IbuprofenSolute carrier organic anion transporter family member 2B1transporter
DB01050IbuprofenMultidrug resistance protein 1transporter
DB01050IbuprofenUDP-glucuronosyltransferase 1-1enzyme
DB01050IbuprofenUDP-glucuronosyltransferase 1-3enzyme
DB01050IbuprofenUDP-glucuronosyltransferase 1-9enzyme
DB01050IbuprofenUDP-glucuronosyltransferase 2B4enzyme
DB01050IbuprofenUDP-glucuronosyltransferase 2B7enzyme
DB01050IbuprofenCytochrome P450 2C8enzyme
DB01050IbuprofenCytochrome P450 2C19enzyme
DB01050IbuprofenProstaglandin G/H synthase 1enzyme
DB01050IbuprofenProstaglandin G/H synthase 2enzyme
DB01050IbuprofenApoptosis regulator Bcl-2target
DB01050IbuprofenThrombomodulintarget
DB01050IbuprofenTissue-type plasminogen activatortarget
DB01050IbuprofenFatty acid-binding protein, intestinaltarget
DB01050IbuprofenPeroxisome proliferator-activated receptor gammatarget
DB01050IbuprofenCystic fibrosis transmembrane conductance regulatortarget
DB01050IbuprofenSolute carrier family 15 member 1target
DB01050IbuprofenPeroxisome proliferator-activated receptor alphatarget
DB08820IvacaftorCystic fibrosis transmembrane conductance regulatortarget
DB08820IvacaftorCytochrome P450 3A4enzyme
DB08820IvacaftorSerum albumincarrier
DB08820IvacaftorAlpha-1-acid glycoprotein 1carrier
DB08820IvacaftorMultidrug resistance protein 1transporter
DB08820IvacaftorCytochrome P450 3A5enzyme
DB09280LumacaftorCytochrome P450 2B6enzyme
DB09280LumacaftorCytochrome P450 2C8enzyme
DB09280LumacaftorCytochrome P450 2C9enzyme
DB09280LumacaftorCytochrome P450 2C19enzyme
DB09280LumacaftorSerum albumincarrier
DB09280LumacaftorCystic fibrosis transmembrane conductance regulatortarget
DB09280LumacaftorCytochrome P450 3A4enzyme
DB09280LumacaftorMultidrug resistance protein 1transporter
DrugDrug NamePhaseStatusCount
DB08820Ivacaftor0Active Not Recruiting1
DB00556Perflutren0Not Yet Recruiting1
DB11104Sulfur hexafluoride0Not Yet Recruiting1
DB129468-cyclopentyl-1,3-dipropylxanthine1Completed1
DB00594Amiloride1Completed1
DB00438Ceftazidime1Completed1
DB00537Ciprofloxacin1Completed2
DB12135Elubrixin1Completed2
DB05076Fenretinide1Completed1
DB05260Gallium nitrate1Active Not Recruiting1
DB01611Hydroxychloroquine1Completed1
DB01167Itraconazole1Completed1
DB08820Ivacaftor1Completed8
DB08820Ivacaftor1Recruiting1
DB00448Lansoprazole1Completed1
DB01137Levofloxacin1Completed2
DB09280Lumacaftor1Completed5
DB00742Mannitol1Completed2
DB01277Mecasermin1Terminated1
DB05914Mesenchymal Stem Cells1Recruiting1
DB12525Molgramostim1Completed1
DB00218Moxifloxacin1Completed1
DB12206N-60221Completed1
DB09140Oxygen1Completed1
DB00082Pegvisomant1Terminated1
DB01132Pioglitazone1Completed1
DB06809Plerixafor1Recruiting1
DB01045Rifampicin1Completed2
DB01261Sitagliptin1Completed1
DB09153Sodium Chloride1Completed1
DB11712Tezacaftor1Completed1
DB11712Tezacaftor1Recruiting1
DB01409Tiotropium1Completed1
DB00684Tobramycin1Completed6
DB03754Tromethamine1Not Yet Recruiting1
DB00512Vancomycin1Completed1
DB00512Vancomycin1Unknown Status1
DB09315Xenon-1331Recruiting1
DB12871Burlulipase1 / 2Completed1
DB00847Cysteamine1 / 2Completed1
DB01645Genistein1 / 2Completed1
DB01645Genistein1 / 2Terminated1
DB08909Glycerol Phenylbutyrate1 / 2Not Yet Recruiting1
DB04335Inosine1 / 2Completed1
DB00033Interferon gamma-1b1 / 2Completed2
DB08820Ivacaftor1 / 2Recruiting1
DB05222KB0011 / 2Completed1
DB00435Nitric Oxide1 / 2Completed1
DB09152Nitrogen1 / 2Completed1
DB06819Phenylbutyric acid1 / 2Completed1
DB06819Phenylbutyric acid1 / 2Terminated1
DB00203Sildenafil1 / 2Completed1
DB00203Sildenafil1 / 2Recruiting1
DB00641Simvastatin1 / 2Withdrawn1
DB09112Sodium Nitrite1 / 2Recruiting1
DB11712Tezacaftor1 / 2Recruiting1
DB00684Tobramycin1 / 2Unknown Status1
DB11195Xylitol1 / 2Active Not Recruiting1
DB11195Xylitol1 / 2Completed1
DB05330ALTU-1352Completed1
DB11961AZD-12362Withdrawn1
DB06151Acetylcysteine2Completed1
DB12193Ajulemic acid2Completed1
DB00058Alpha-1-proteinase inhibitor2Completed2
DB00058Alpha-1-proteinase inhibitor2Terminated1
DB11863Alvelestat2Completed1
DB00594Amiloride2Completed1
DB00321Amitriptyline2Completed1
DB00321Amitriptyline2Unknown Status1
DB05016Ataluren2Completed4
DB00207Azithromycin2Unknown Status1
DB00355Aztreonam2Completed2
DB00355Aztreonam2Recruiting1
DB00878Chlorhexidine2Active Not Recruiting1
DB00878Chlorhexidine2Completed1
DB11121Chloroxylenol2Active Not Recruiting1
DB11121Chloroxylenol2Completed4
DB00537Ciprofloxacin2Completed2
DB00803Colistin2Completed1
DB00847Cysteamine2Recruiting1
DB04983Denufosol2Completed3
DB01396Digitoxin2Completed1
DB11292Docosahexaenoate2Completed1
DB00003Dornase alfa2Completed2
DB00003Dornase alfa2Unknown Status1
DB00254Doxycycline2Active Not Recruiting1
DB12135Elubrixin2Completed1
DB00736Esomeprazole2Terminated1
DB12296GS-57452Terminated1
DB05260Gallium nitrate2Recruiting1
DB00798Gentamicin2Terminated1
DB00143Glutathione2Recruiting1
DB01167Itraconazole2Completed1
DB08820Ivacaftor2Active Not Recruiting1
DB08820Ivacaftor2Completed10
DB08820Ivacaftor2Recruiting3
DB08820Ivacaftor2Terminated2
DB00125L-Arginine2Completed1
DB05029Lancovutide2Completed1
DB01137Levofloxacin2Completed1
DB00601Linezolid2Unknown Status1
DB00678Losartan2Not Yet Recruiting1
DB09280Lumacaftor2Active Not Recruiting1
DB09280Lumacaftor2Completed3
DB00742Mannitol2Completed3
DB00742Mannitol2Unknown Status1
DB09337Medical air2Completed1
DB00419Miglustat2Completed2
DB00419Miglustat2Terminated1
DB01017Minocycline2Completed1
DB00410Mupirocin2Active Not Recruiting1
DB00410Mupirocin2Completed1
DB00435Nitric Oxide2Completed1
DB00435Nitric Oxide2Recruiting1
DB09152Nitrogen2Completed1
DB09140Oxygen2Completed1
DB00082Pegvisomant2Completed1
DB01045Rifampicin2Active Not Recruiting1
DB01045Rifampicin2Completed1
DB08931Riociguat2Terminated1
DB00360Sapropterin2Completed1
DB00203Sildenafil2Active Not Recruiting1
DB00203Sildenafil2Completed1
DB01261Sitagliptin2Terminated1
DB00052Somatotropin2Completed1
DB01015Sulfamethoxazole2Active Not Recruiting1
DB01015Sulfamethoxazole2Completed1
DB11712Tezacaftor2Completed4
DB11712Tezacaftor2Recruiting3
DB01409Tiotropium2Completed1
DB00684Tobramycin2Completed3
DB00440Trimethoprim2Active Not Recruiting1
DB00440Trimethoprim2Completed1
DB01586Ursodeoxycholic acid2Unknown Status1
DB00862Vardenafil2Suspended1
DB00582Voriconazole2Completed1
DB09145Water2Active Not Recruiting1
DB01307Insulin Detemir2 / 3Recruiting1
DB00419Miglustat2 / 3Recruiting1
DB05330ALTU-1353Completed2
DB00630Alendronic acid3Completed1
DB05016Ataluren3Active Not Recruiting1
DB05016Ataluren3Completed2
DB05016Ataluren3Terminated2
DB00207Azithromycin3Active Not Recruiting1
DB00207Azithromycin3Recruiting1
DB00355Aztreonam3Completed3
DB00355Aztreonam3Recruiting1
DB00003Dornase alfa3Completed2
DB00003Dornase alfa3Withdrawn1
DB00143Glutathione3Unknown Status1
DB01307Insulin Detemir3Recruiting1
DB00047Insulin Glargine3Unknown Status1
DB00030Insulin Human3Completed1
DB08820Ivacaftor3Active Not Recruiting3
DB08820Ivacaftor3Completed15
DB08820Ivacaftor3Enrolling by Invitation2
DB08820Ivacaftor3Recruiting5
DB08820Ivacaftor3Terminated1
DB01137Levofloxacin3Completed2
DB09280Lumacaftor3Active Not Recruiting1
DB09280Lumacaftor3Completed4
DB09280Lumacaftor3Enrolling by Invitation1
DB00742Mannitol3Completed1
DB00085Pancrelipase3Completed2
DB05356Pancrelipase3Completed2
DB13147Pancrelipase lipase3Completed1
DB00912Repaglinide3Completed2
DB01261Sitagliptin3Terminated1
DB09153Sodium Chloride3Recruiting1
DB11712Tezacaftor3Active Not Recruiting1
DB11712Tezacaftor3Completed3
DB11712Tezacaftor3Enrolling by Invitation1
DB11712Tezacaftor3Recruiting1
DB01409Tiotropium3Completed1
DB00684Tobramycin3Active Not Recruiting1
DB00684Tobramycin3Completed8
DB00684Tobramycin3Recruiting2
DB06151Acetylcysteine4Terminated1
DB00630Alendronic acid4Completed2
DB05016Ataluren4Active Not Recruiting1
DB09060Avibactam4Completed1
DB00207Azithromycin4Completed2
DB00207Azithromycin4Enrolling by Invitation1
DB00207Azithromycin4Recruiting1
DB00355Aztreonam4Recruiting1
DB00438Ceftazidime4Completed1
DB00438Ceftazidime4Terminated1
DB00438Ceftazidime4Unknown Status1
DB09050Ceftolozane4Completed1
DB01111Colistimethate4Completed1
DB00803Colistin4Recruiting1
DB00003Dornase alfa4Completed2
DB00003Dornase alfa4Terminated2
DB00254Doxycycline4Completed1
DB01167Itraconazole4Completed1
DB01167Itraconazole4Terminated1
DB08820Ivacaftor4Active Not Recruiting2
DB08820Ivacaftor4Terminated1
DB09280Lumacaftor4Active Not Recruiting1
DB09280Lumacaftor4Terminated1
DB00760Meropenem4Completed1
DB00760Meropenem4Unknown Status1
DB00043Omalizumab4Terminated1
DB05356Pancrelipase4Completed2
DB00085Pancrelipase4Terminated1
DB13147Pancrelipase lipase4Terminated1
DB00319Piperacillin4Terminated1
DB01045Rifampicin4Not Yet Recruiting1
DB00884Risedronate4Completed1
DB01606Tazobactam4Completed1
DB01606Tazobactam4Terminated1
DB06402Telavancin4Recruiting1
DB00684Tobramycin4Completed3
DB00684Tobramycin4Recruiting1
DB00684Tobramycin4Unknown Status1
DB00399Zoledronic acid4Withdrawn1
DB00630Alendronic acidNot AvailableCompleted1
DB00479AmikacinNot AvailableCompleted1
DB00479AmikacinNot AvailableRecruiting1
DB00594AmilorideNot AvailableCompleted1
DB00207AzithromycinNot AvailableCompleted2
DB00355AztreonamNot AvailableApproved for Marketing2
DB00355AztreonamNot AvailableCompleted1
DB00626BacitracinNot AvailableWithdrawn1
DB01373CalciumNot AvailableCompleted1
DB06724Calcium CarbonateNot AvailableCompleted1
DB06415CalfactantNot AvailableCompleted1
DB00438CeftazidimeNot AvailableCompleted1
DB00438CeftazidimeNot AvailableEnrolling by Invitation1
DB00438CeftazidimeNot AvailableRecruiting1
DB11121ChloroxylenolNot AvailableRecruiting1
DB00169CholecalciferolNot AvailableCompleted2
DB01211ClarithromycinNot AvailableCompleted1
DB00803ColistinNot AvailableRecruiting1
DB00254DoxycyclineNot AvailableCompleted1
DB00153ErgocalciferolNot AvailableCompleted1
DB00330EthambutolNot AvailableCompleted1
DB00977Ethinyl EstradiolNot AvailableRecruiting1
DB00588Fluticasone propionateNot AvailableCompleted1
DB11895GhrelinNot AvailableUnknown Status1
DB09341GlucoseNot AvailableTerminated1
DB10989Hepatitis A VaccineNot AvailableRecruiting1
DB01050IbuprofenNot AvailableCompleted4
DB01592IronNot AvailableCompleted1
DB08820IvacaftorNot AvailableActive Not Recruiting1
DB08820IvacaftorNot AvailableApproved for Marketing1
DB08820IvacaftorNot AvailableAvailable1
DB08820IvacaftorNot AvailableNot Yet Recruiting2
DB08820IvacaftorNot AvailableRecruiting1
DB08820IvacaftorNot AvailableUnknown Status1
DB00149L-LeucineNot AvailableTerminated1
DB01046LubiprostoneNot AvailableCompleted1
DB09280LumacaftorNot AvailableNot Yet Recruiting2
DB09280LumacaftorNot AvailableRecruiting1
DB00742MannitolNot AvailableRecruiting1
DB00760MeropenemNot AvailableCompleted1
DB00760MeropenemNot AvailableEnrolling by Invitation1
DB00688Mycophenolate mofetilNot AvailableUnknown Status1
DB00994NeomycinNot AvailableWithdrawn1
DB00717NorethisteroneNot AvailableRecruiting1
DB00085PancrelipaseNot AvailableCompleted1
DB13147Pancrelipase lipaseNot AvailableCompleted1
DB00082PegvisomantNot AvailableUnknown Status1
DB01132PioglitazoneNot AvailableCompleted2
DB00781Polymyxin B SulfateNot AvailableWithdrawn1
DB09345PramocaineNot AvailableWithdrawn1
DB01045RifampicinNot AvailableCompleted1
DB01001SalbutamolNot AvailableCompleted1
DB01001SalbutamolNot AvailableRecruiting1
DB01001SalbutamolNot AvailableSuspended1
DB00938SalmeterolNot AvailableSuspended1
DB06335SaxagliptinNot AvailableUnknown Status2
DB00641SimvastatinNot AvailableCompleted1
DB01261SitagliptinNot AvailableRecruiting1
DB09153Sodium ChlorideNot AvailableCompleted1
DB08834Tauroursodeoxycholic acidNot AvailableCompleted1
DB11712TezacaftorNot AvailableAvailable1
DB00684TobramycinNot AvailableCompleted2
DB00684TobramycinNot AvailableRecruiting2
DB02745UridineNot AvailableCompleted1
DB01586Ursodeoxycholic acidNot AvailableCompleted1
DB01593ZincNot AvailableCompleted1